IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis

Journal of Immunology

Volumn 167, Issue 7, 2001, Pages 4075-4082

  McInnes, I B ^a   Illei, G C ^a   Danning, C L ^a   Yarboro, C H ^a   Crane, M ^a   Kuroiwa, T ^a   Schlimgen, R ^a   Lee, E ^a   Foster, B ^a   Flemming, D ^a   Prussin, C ^a   Fleisher, T A ^a   Boumpas, D T ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; ARTICULAR CARTILAGE; CLINICAL ARTICLE; CYTOKINE RELEASE; DISEASE ACTIVITY; EFFECTOR CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MALE; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SKIN BIOPSY; SKIN DISEASE; T LYMPHOCYTE ACTIVATION;

EID: 0035478652     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.7.4075     Document Type: Article

References (52)

1. Interleukin 10 (IL 10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
2. Interleukin (IL)-10 inhibits nuclear factor κB (NFκB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms
3. Interleukin-10
4. Balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10
5. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monccytes
6. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression
7. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-γ or by interleukin-10
8. Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells
9. Contact with T cells modulates monocyte IL-10 production: Role of T cell membrane TNF-α
10. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10
11. + T cell clones and resting T cells: Specific inhibition of IL-2 production and proliferation
12. + T cells
13. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
14. Antigen presentation by human dermal microvascular endothelial cells: Immunoregulatory effect of IFN-γ and IL-10
15. A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation
16. Interleukin-10 modulates type 1 collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts
17. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes
18. Interleukin-10 selectively inhibits osteolastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system
19. The cytokine network in lesional and lesion free psoriatic skin is characterized by a T helper type 1 cell mediated response
20. T cells involved in psoriasis vulgaris belong to the Th1 subset
21. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis
22. Keratinocyte interleukin-10 expression is up-regulated in tape stripped skin, poison ivy dermatitis and Sezary syndrome, but not in psoriatic plaques
23. IL-10 is a key cytokine in psoriasis: Proof of principle by IL-10 therapy: A new therapeutic approach
24. Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1α in normal and psoriatic skin: Decreased expression of IRAP in psoriatic lesional epidermis
25. Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use
26. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network
27. Macrophage derived cytokine and NFκB p65 expression in psoriatic arthritis synovial membrane and skin
28. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
29. Vascular proliferation and angiogenic factors in psoriasis
30. Synovial cytokine and growth factor regulation of MMPs/TIMPs: Implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients
31. A randomized, controlled trial of IL-10 in humans: Inhibition of inflammatory cytokine production and immune responses
32. Interleukin 10 treatment for rheumatoid arthritis
33. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease: Crohn's Disease Study Group
34. Severe psoriasis: Oral therapy with a new retinoid
35. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
36. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients
37. - lymphocyte subpopulation
38. Shift toward T lymphocytes with a T helper 1 cytokine secretion profile in the joints of patients with rheumatoid arthritis
39. Divergent T-cell cytokine patterns in inflammatory arthritis
40. CCR5 is characteristic of Th1 lymphocytes
41. Interleukin-18
42. P-and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues
43. 3 antagonist
44. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-α (cA2) therapy
45. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells
46. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papilloma virus specific CD8 cytotoxic T lymphocytes
47. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10: Differential modulation of B7-1(CD80) and B7-2 (CD86) expression
48. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper I but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin
49. Interleukin-10 induces Eselectin on small and large blood vessel endothelial cells
50. Regulation of tumor growth and metastasis by interleukin-10: The melanoma experience
51. Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial
52. 1α,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on SCID mice